RxREVU
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|
Revenues | 3.5m | 4.6m | 8.8m | 9.1m |
% growth | - | 31 % | 90 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Early VC | |
N/A | $460k | Seed | |
N/A | $750k | Seed | |
N/A | $1.3m | Seed | |
N/A | $4.7m | Early VC | |
$15.9m | Series A | ||
$7.0m Valuation: $79.5m | Series B | ||
$8.0m Valuation: $79.5m | Late VC | ||
Total Funding | CAD52.0m |
Related Content
Recent News about RxREVU
EditRxRevu operates in the healthcare technology sector, focusing on providing real-time prescription benefit data to healthcare providers. The company serves hospitals, health systems, and electronic health record (EHR) vendors across the United States. RxRevu's core product is a price transparency network that delivers patient-specific cost and coverage information at the point of care. This service helps healthcare providers make informed prescribing decisions, ultimately aiming to improve patient outcomes and reduce healthcare costs. The business model revolves around partnerships with healthcare organizations and EHR vendors, generating revenue through subscription fees and data-sharing agreements. By integrating its solution into native EHR workflows, RxRevu ensures that providers have seamless access to critical cost and coverage data during patient consultations. The company has been recognized for its rapid growth and innovation, as evidenced by its inclusion in the Inc. 5000 list of fastest-growing private companies.
Keywords: price transparency, healthcare technology, prescription benefit data, EHR integration, patient-specific information, cost reduction, value-based care, healthcare providers, real-time data, subscription model.